Navigation Links
GeneChoice TEMPase II DNA Polymerase from GeneChoice, Inc.

ProductsGeneChoice TEMPase II DNA Polymerase from GeneChoice, Inc.
Company GeneChoice, Inc.
Item GeneChoice TEMPase II DNA Polymerase
Price $220.00
Description • Heat activated
• Eliminates nonspecific products due to inactivity at room temperature
• Excellent specificity allows extension through DNA regions which contain repeats and secondary structures
• Leaves an 'A' overhang

TEMPase II is a chemically modified form of GeneChoice DNA Polymerase that remains inactive at room temperature and works optimally in a distinctive buffer system.

TEMPase II is useful for performing automated hot start amplification due to its thermal activation at a temperature well above optimal annealing. The enzyme remains inactive until the time, temperature, and pH are optimal. During hot start, primers bind only to their specific target, and polymerase activity is directed exclusively to that target. As a result, only the region of interest is amplified, which increases sensitivity and yield while reducing non-specific background amplification.

Once the reaction reaches optimal annealing temperatures after a 15 minute activation step at 95C, the enzyme stays activated in the reaction.

Since the enzyme is chemically modified for hot start (no antibody), there is no material from animal sources, i.e., there is no possibility for biological contamination.

10X TEMPase II Reaction Buffer - Combination of (NH4)2S04 and KCl, 15 mM MgCl2, 1% Tween 20.
25 mM MgCl2 Solution - Supplied.
Info GeneChoice, Inc.GeneChoice, Inc.
7307 Governors Way
Frederick, MD 21703 USA

Call GeneChoice, Inc. to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-772-8354
Customer Service: 866-636-2200
Fax Number: 301-620-0162
Web Site: http://www.genechoiceinc.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. GeneChoice Taq DNA Polymerase With Standard Buffer from GeneChoice, Inc.
2. GeneChoice Taq DNA Polymerase With Ammonium Buffer from GeneChoice, Inc.
3. GeneChoice Taq DNA Polymerase With Magnesium Free Standard Buffer from GeneChoice, Inc.
4. GeneChoice RNA Safe Recombinant Ribonuclease Inhibitor from GeneChoice, Inc.
5. T4 DNA Polymerase from Roche Applied Science
6. T4 DNA Polymerase from Roche Applied Science
7. Poly A Polymerase from Invitrogen
8. iTaq DNA Polymerase, 250 U from Bio-Rad
9. iTaq DNA Polymerase, 5,000 U from Bio-Rad
10. Taq DNA Polymerase, 500 U (2 x 250 U) without dNTP from Bioneer, Inc.
11. T4 DNA Polymerase from Invitrogen
...
... Product Rabbit polyclonal to JNK1 (phospho T183 ... to an internal domain containing phosphorylated T183/Y185. ... and Rat. Not yet tested in other species. ... several subgroups, including the ERK, JNK, and p38 ...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... solid. Increases the expression of glutathione peroxidase. ... 2 O. Unstable in aqueous solutions; reconstitute ... 3211-76-5, M.W. 196.1. References: Merck Index ... A.F. 1995. Biochem. J. 306, ...
Biology Products:
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Reproductive medicine is one of today,s most exciting ... of medical ,firsts, new rulings by regulatory bodies or ... in the field, ethicists, legislators, the media and the ... All sessions are open to journalists and registration is ...
... It might sound like a mashup of monster movies, ... attacked its prey, reconstructing a killing that took place 4 ... is incredibly rare, but by careful, forensic-style analysis of bite ... based in Pisa, Italy, have reconstructed the events that led ...
... , This release is available in French . ... Dr. Hanadi Sleiman has achieved a major breakthrough in the development ... drugs to specific diseased cells. Sleiman explains that the research involves ... used as the genetic code for life, it becomes a kind ...
Cached Biology News:ESHRE Annual Meeting, June 27-30 in Rome 2Jaws -- 4 million B.C. 2
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8